For decades, hormone replacement therapy carried a reputation that kept many women away from it entirely. Safety warnings, concerns about cancer risks and lingering anxiety from older research made HRT one of the most debated treatments in women’s medicine. But that picture is shifting and a new large-scale study is offering some of the clearest evidence yet that the timing of when a woman starts the therapy may matter more than previously understood.
What HRT actually does
As women move through perimenopause and into menopause, the ovaries gradually produce less estrogen and progesterone hormones that regulate everything from body temperature and mood to bone density and cardiovascular function. Hormone replacement therapy, now more commonly referred to as menopausal hormone therapy (MHT), works by restoring those declining levels.
The treatment has long been used to address familiar symptoms like hot flashes, night sweats and sleep disruption. But growing research suggests its benefits may extend well beyond day to day symptom management, particularly when treatment begins early.
How HRT got its complicated reputation
Much of the concern surrounding HRT traces back to a single influential study the Women’s Health Initiative, published in 2002 which raised alarms about potential links between hormone therapy and increased risks of breast cancer and cardiovascular events. The fallout was significant. Women avoided the treatment in large numbers, even as menopausal symptoms continued to affect their sleep, mental health and quality of life.
But experts and federal regulators have since taken a harder look at those findings. The Women’s Health Initiative study primarily involved women with an average age of 63, more than a decade past the typical onset of menopause, and used hormone formulations that are no longer standard practice. In November 2025, the U.S. Food and Drug Administration announced it would remove the long-standing black box warnings from menopausal HRT products, describing earlier risk messaging as a distortion of the evidence.
What the new research found
The 2025 study, analyzed more than 120 million patient records, making it one of the most expansive real world investigations into MHT conducted to date. Researchers found no increased association of heart attack, stroke or breast cancer among women who started MHT before menopause compared with those who started after. That finding alone challenges assumptions that have shaped clinical guidance for more than two decades.
Some data in the study also pointed to a notably lower breast cancer risk as much as 60% among women who began therapy earlier. The study’s authors are careful to note, however, that the research identifies associations rather than direct cause and effect, and that the lower risk figure should not be interpreted as proof of a protective benefit.
Why timing may make all the difference
Researchers believe the benefits tied to earlier treatment may be connected to something broader than the hormones themselves. Women who seek out and begin MHT earlier tend to be more actively engaged with their healthcare providers, which often means underlying conditions like hypertension which frequently goes undetected due to a lack of obvious symptoms are identified and managed sooner.
That engagement matters. Timely symptom relief may also make it easier for women to maintain the foundational health habits that reduce long term risk, regular cardiovascular exercise, strength training, consistent sleep and nutritious eating. When symptoms are disrupting those basics, the downstream effects on long-term health can be significant.
The FDA’s own 2025 guidance supports this picture. Research it cited indicates that women who begin HRT within 10 years of menopause generally before age 60 may face reduced risks of bone fractures, all cause mortality, cardiovascular disease and, in some studies, even Alzheimer’s disease.
What women should do now
Experts are encouraging women to start the conversation with their doctors earlier than they might think necessary ideally in their 40s, when the first signs of perimenopause may begin to appear, or even before symptoms arrive at all.
The broader message from researchers is that the years between a woman’s mid 40s and mid 50s represent a period of significant metabolic change, and one where many women are least likely to prioritize their own healthcare. Demands from careers, children and aging parents frequently push personal health to the back. But doctors say this is precisely the window when preventive care including cancer screenings, vaccinations and an honest conversation about hormonal health can have the most lasting impact.
Starting that conversation early doesn’t necessarily mean starting treatment immediately. It means understanding the options, monitoring symptoms and staying connected to a provider who can help navigate the transition thoughtfully before a health concern becomes a health crisis.
